These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38659199)

  • 1. MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.
    Liu Y; Qi L; Ye B; Wang A; Lu J; Qu L; Luo P; Wang L; Jiang A
    Cancer Biol Ther; 2024 Dec; 25(1):2345977. PubMed ID: 38659199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC family reshapes the immune microenvironment and therapy sensitivity in clear cell renal cell carcinoma.
    Huang G; Zhan X; Shen L; Lou L; Dai Y; Jiang A; Gao Y; Wang Y; Xie X; Zhang J
    Clin Exp Med; 2024 Sep; 24(1):212. PubMed ID: 39249558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anoikis resistance regulates immune infiltration and drug sensitivity in clear-cell renal cell carcinoma: insights from multi omics, single cell analysis and
    Wen X; Hou J; Qi T; Cheng X; Liao G; Fang S; Xiao S; Qiu L; Wei W
    Front Immunol; 2024; 15():1427475. PubMed ID: 38953023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
    Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
    Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma.
    Wu G; Li T; Chen Y; Ye S; Zhou S; Tian X; Anwaier A; Zhu S; Xu W; Hao X; Ye D; Zhang H
    Clin Exp Med; 2024 Jul; 24(1):152. PubMed ID: 38970690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
    Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
    Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
    Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
    Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
    Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma.
    Jiang A; Liu Y; Zhu B; Fang Y; Qu L; Yang Q; Luo P; Cai C; Wang L
    Clin Genitourin Cancer; 2024 Apr; 22(2):497-513. PubMed ID: 38245436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
    Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
    Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDK promotes M2 macrophage polarization to remodel the tumour microenvironment in clear cell renal cell carcinoma.
    Shi N; Chen S; Wang D; Wu T; Zhang N; Chen M; Ding X
    Sci Rep; 2024 Aug; 14(1):18254. PubMed ID: 39107475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored.
    Yoon JY; Gedye C; Paterson J; Ailles L
    BMC Cancer; 2020 Apr; 20(1):272. PubMed ID: 32245446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Phenotype-Genotype Associations in Primary Clear Cell Renal Cell Carcinoma and Matched Metastatic Tissue.
    Sobottka B; Vetter V; Banaei-Esfahani A; Nowak M; Lorch A; Sirek A; Mertz KD; Brunelli M; Berthold D; de Leval L; Kahraman A; Koelzer VH; Moch H
    Mod Pathol; 2024 Oct; 37(10):100558. PubMed ID: 38969270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unfolding the mysteries of heterogeneity from a high-resolution perspective: integration analysis of single-cell multi-omics and spatial omics revealed functionally heterogeneous cancer cells in ccRCC.
    Zheng J; Lu W; Wang C; Chen S; Zhang Q; Su C
    Aging (Albany NY); 2024 Jun; 16(13):10943-10971. PubMed ID: 38944814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma.
    Qiu X; Gu Y; Ni Y; Li Q
    Biomed Res Int; 2020; 2020():2064582. PubMed ID: 33178820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
    Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
    Front Immunol; 2022; 13():861328. PubMed ID: 35479084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC).
    Liu S; Li S; Wang Y; Wang F; Zhang L; Xian S; Yang D; Yuan M; Dai F; Zhao X; Liu Y; Jin Y; Zeng Z; Mahgoub OKA; Zhou C; Cheng Y
    J Cell Biochem; 2020 Mar; 121(3):2571-2581. PubMed ID: 31823423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.